AVLN

The company specializes in creating inhaled formulations of existing oral medicines, with the goal of delivering these drugs directly to the lungs. This approach is designed to improve efficacy and reduce systemic side effects for patients. Avalyn's current pipeline is concentrated on treating pulmonary fibrosis, a group of serious lung conditions characterized by scarring of the lung tissue. Its leading investigational products include AP01 and AP02, which are inhaled versions of the established antifibrotic drugs pirfenidone and nintedanib, respectively. These are intended for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis.

Avalyn is also developing AP03, a fixed-dose combination product that aims to deliver both pirfenidone and nintedanib via inhalation. By focusing on inhaled delivery for rare lung diseases, the company seeks to address unmet medical needs where current treatments have limitations. Avalyn Pharma was originally incorporated in 2011 as Genoa Pharmaceuticals, Inc., and adopted its current name in July 2017. As a clinical-stage company, its activities are centered on advancing these therapies through clinical development.